Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.3208
-0.0418 (-11.53%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bluebird Bio
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
November 15, 2024
Bluebird Bio's Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns.
Via
Benzinga
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
November 14, 2024
From
bluebird bio, Inc.
Via
Business Wire
Exploring bluebird bio's Earnings Expectations
November 13, 2024
Via
Benzinga
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
November 06, 2024
From
bluebird bio, Inc.
Via
Business Wire
The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts
September 25, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About bluebird bio
August 15, 2024
Via
Benzinga
Earnings Scheduled For November 14, 2024
November 14, 2024
Via
Benzinga
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
November 05, 2024
From
bluebird bio, Inc.
Via
Business Wire
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
October 11, 2024
A recent report reveals an increase in cancer cases among children treated with Bluebird Bio's Skysona gene therapy, raising concerns about the therapy's safety. Seven children in clinical trials have...
Via
Benzinga
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
September 27, 2024
From
bluebird bio, Inc.
Via
Business Wire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
September 26, 2024
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
Via
Investor's Business Daily
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
September 24, 2024
Bluebird bio announces restructuring plans to reduce costs by 20% and achieve cash flow break-even by late 2025. The initiative includes a 25% workforce reduction and focuses on advancing key gene...
Via
Benzinga
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
September 24, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
September 13, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces September Investor Events
August 28, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Receipt of Expected Notices from Nasdaq
August 23, 2024
From
bluebird bio, Inc.
Via
Business Wire
This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
August 15, 2024
Via
Benzinga
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
August 14, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Second Quarter 2024 Results Call Date
August 12, 2024
From
bluebird bio, Inc.
Via
Business Wire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
August 02, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
bluebird bio, Inc.
Via
Business Wire
BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 12, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
bluebird bio, Inc.
Via
Business Wire
BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
June 27, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
bluebird bio Appoints O. James Sterling as Chief Financial Officer
May 29, 2024
From
bluebird bio, Inc.
Via
Business Wire
BLUE FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important May 28 Deadline in Securities Class Action - BLUE
May 28, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
BLUE FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important May 28 Deadline in Securities Class Action - BLUE
May 28, 2024
WHY: NEW YORK, NY - (NewMediaWire) - May 28, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. (NASDAQ: BLUE) between April 24, 2023 and...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
DEADLINE TODAY: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm
May 28, 2024
From
Schall Law
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.